Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 4/20 | 0.33 |
| ▸ | MMP3 | P08254 | 4/20 | 0.33 |
| ▸ | MMP7 | P09237 | 3/20 | 0.33 |
| ▸ | MMP8 | P22894 | 3/20 | 0.33 |
| ▸ | MMP9 | P14780 | 2/20 | 0.33 |
| ▸ | MMP14 | P50281 | 2/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 3/20 | 0.32 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.32 |
| ▸ | MMP12 | P39900 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4843912 | 1.00 | CYP2C19 (0.42) | CYP2C19SMN1; SMN2LMNAUTS2RMTOR | |
| SCHEMBL14254594 | 0.84 | OPRK1 (0.51) | LMNAOPRK1 | |
| SCHEMBL14254584 | 0.84 | OPRK1 (0.51) | LMNAOPRK1 | |
| SCHEMBL17497762 | 0.82 | GAA (0.50) | CYP2C19 | |
| SCHEMBL17497365 | 0.82 | GAA (0.50) | CYP2C19 | |
| SCHEMBL17497362 | 0.82 | GAA (0.50) | CYP2C19 | |
| SCHEMBL17497769 | 0.82 | GAA (0.50) | CYP2C19 | |
| SCHEMBL17497546 | 0.82 | GAA (0.50) | CYP2C19 | |
| SCHEMBL8751571 | 0.74 | LMNA (0.47) | CYP2C19LMNAMTOR | |
| SCHEMBL12495087 | 0.72 | TSHR (0.41) | CYP2C19SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342007-B2 | Lactams and uses thereof | ASTRAZENECA AB (SE) | 2008-03-11 | — | — | US | disclosed |
| US-20060183732-A1 | Novel lactams and uses thereof | ASTRAZENECA AB (SE) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183732-A1 | Novel lactams and uses thereof | BACE1, BACE2, APP | CYP2C19 841/4885SMN1; SMN2 975/4885LMNA 2273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.